Biogen Buys Apellis for $5.6B to Expand Kidney Drugs

Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, marking one of its largest-ever deals to bolster its drug portfolio. The acquisition expands Biogen’s focus on immunology and rare diseases, particularly kidney-related treatments, strengthening its pipeline in high-need therapeutic areas. Announced in April 2026, the deal reflects Biogen’s strategic push into specialized markets amid growing competition in biopharmaceuticals. Apellis’s complementary therapies align with Biogen’s long-term growth strategy, targeting unmet medical needs in rare and chronic conditions. The $5.6 billion price underscores Biogen’s confidence in Apellis’s clinical assets and commercial potential in the expanding immunology sector.